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ABSTRACT 
Background: Osteoporosis is an age-related skeletal condition of bone, with increasing prevalence in older 
populations. Insufficiency of the bone is associated with increased disability and mortality. Vertebral fractures 
are commonly secondary to osteoporosis, however only a proportion of patients may present clinically with 
identifiable symptoms. Percutaneous vertebroplasty is an interventional method of managing such patients.  
 
Aim: To determine the role of percutaneous vertebroplasty in managing patients with osteoporotic vertebral 
fractures.  
 
Methods: Electronic databases including MEDLINE, Cochrane Library and NHS Evidence were searched for 
meta-analyses and randomised controlled trials, with some provision given to expert reviews due to the small 
pool of publications available. Search terms used included “osteoporosis and vertebral fractures”, 
“vertebroplasty and osteoporosis”, “percutaneous vertebroplasty in the management of osteoporosis”, 
“vertebral body cement augmentation”, and “balloon kyphoplasty”.   
 
Results: Vertebroplasty reduces pain in the short-term (up to 2 weeks) after surgery and has sustained effects 
in improving quality of life. The long-term effects are difficult to establish due to the underlying osteoporosis 
disease progression and comorbidities.   
 
Conclusion: Vertebroplasty is worthwhile in treating acute vertebral fractures associated with pain. However 
more research is needed to fully determine its effectiveness in the long term.  
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Introduction 
Osteoporosis is a systemic skeletal condition 
affecting populations worldwide, causing an 
estimated 8.9 million fractures each year.1 The 
increase in bone damage and thus subsequent 
fragility fractures result from the reduction in bone 
mass and changes in the micro-architecture of bone 
tissue, which characterises osteoporosis.2 As the 
likelihood of fracture and thus mortality increases 
with age,3 treating osteoporosis and associated 
fractures in the ageing population may increase the 
financial strain on the healthcare service. The three 
commonest osteoporotic fractures are those of the 
distal radius, proximal femur, and vertebrae.3 In the 
UK, the cost of treating all osteoporotic fractures in 
postmenopausal women has been predicted to 
exceed £2.1 billion by 2020.4  
 
The spectrum of symptoms associated with 
vertebral fractures can range from asymptomatic to 
severe debilitating pain. Conservative management 
with analgesia does not always serve as a 
satisfactory treatment option for patients and, in 
such cases, a procedure such as vertebroplasty may 
be considered. This review aims to consider the 
literature surrounding this intervention to determine 
its role in current and future management of 
osteoporotic vertebral fractures. 
 
Methods 
Relevant resources were identified from a search of 
the MEDLINE database. Broad search terms such as 
“osteoporosis and vertebral fractures” were used 
initially, before refining to “percutaneous 
vertebroplasty in the management of 
osteoporosis”, which returned 93 publications when 
restricted to those in English. The dates of 
publication were not limited. The Cochrane Library 
yielded a further 8 results from the search terms 
“vertebroplasty and osteoporosis”. NHS Evidence 
was used for contributing evidence as well as current 
recommended guidelines surrounding the topic; 
search terms such as “vertebral body cement 
augmentation” and “balloon kyphoplasty” were 
used.   
 
Initial studies were selected by their titles and 
abstracts, with focus on osteoporotic vertebral 
fractures and the specific mention of intervention by 
vertebroplasty, with or without comparison with 
other methods of management and treatment. 
Particular care was given to include highly graded 
evidence such as systematic reviews and 
randomised controlled trials; however, due to the 
sparse nature of current research, expert opinion 
reviews were also included. 
 
Vertebral Fractures 
Vertebral fractures are an example of an 
osteoporotic fragility fracture; that is, a low trauma 
fracture experienced from the force equivalent to a 
fall from standing height or less, exacerbated by the 
reduction in bone density characteristic of 
osteoporosis.3 However, despite osteoporosis 
being the commonest cause of vertebral fracture, it 
is also relevant to note vertebral fractures can be 
caused by trauma or malignancy.5   
 
Approximately one-third of vertebral fractures 
present clinically with identifiable symptoms.6 They 
are difficult to diagnose at presentation, 
compounded by the low-impact trauma nature of 
the mechanism of injury which the patient may not 
be able to recollect. Therefore, recognition of 
clinical features or incidental imaging may give the 
first indication of a possible injury. Clinical features 
that would suggest the presence of a vertebral 
fracture are loss of height, exaggerated kyphosis of 
the spine, and back pain – typically in the thoracic 
or lumbar spine – as well as respiratory and 
gastrointestinal problems in more severe cases7; all 
of which can impact on one’s daily activities and 
quality of life. Pain experienced in conjunction with 
a vertebral fracture is most prominent in the initial 
weeks following injury; however, pain does not 
subside for all patients during this time period and 
may last for months.8 
 
According to the classification formulated by 
Genant et al., a loss of 20% or more of the vertebral 
height constitutes a fracture.9 The three categories 
of vertebral fracture – wedge, biconcave, and crush 
– can be seen in Figure 1,10 with wedge fractures 
being the most common in osteoporotic patients.11  
 
Vertebral fractures may be distinguished by 
comparison of anterior, mid, and posterior vertebral 
height. For example, a wedge fracture may exhibit 
a loss of anterior vertebral height. A lateral 
radiograph allows the vertebrae to be assessed for 
the presence or absence of these described 
fractures. While CT imaging gives a more 
comprehensive three-dimensional view, further 
detail and ageing of fractures is difficult. One review 
mentions the role of the bone scan in ageing 
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fractures7 while another study reports favouring it for 
distinguishing between painful and healed fractures 
as it provides a functional assessment of bone 
turnover.12 MRI is another imaging modality often 
considered owing to its strength at accurately 
pinpointing the level of injury as well as 
differentiating between fractures of different ages 
by the presence of bone marrow oedema. A small 
retrospective study concluded that MRI was 
equivalent to bone scanning in selecting patients 
suitable for vertebroplasty. MRI has the potential to 
expand into using short tau inversion recovery (STIR) 
sequences though more research needs to be 
undertaken to determine its efficacy.13 A suitable 
imaging technique should be employed for 
assessment and planning of a vertebroplasty, with 
emphasis on detection of more recent fractures. 
 
 
Figure 1 
 
The current treatment of osteoporotic vertebral 
fractures as recommended by NICE aims to “restore 
mobility, reduce pain and minimise the incidence of 
new fractures”. This may comprise analgesia, 
physical therapy, and a well-established regimen of 
pharmacological agents to manage ongoing 
osteoporosis, as well as interventional treatments 
such as percutaneous vertebroplasty and balloon 
kyphoplasty.8 This review will solely discuss the use 
of vertebroplasty in treating vertebral fractures.  
 
Outline of vertebroplasty procedure 
Percutaneous vertebroplasty is a minimally invasive 
surgical procedure. First used in 1987 for the 
treatment of haemangiomas, it later became a 
management option in osteoporosis. It involves the 
injection of bone cement, typically 
polymethylmethacrylate (PMMA), into a fractured 
vertebra, carried out under fluoroscopy guidance. 
Entry is gained through the pedicle of the vertebra, 
and the approach may be unilateral or bilateral.  
 
The procedure can be performed under local or 
general anaesthetic, with the patient in a prone 
position. After the PMMA has been injected, the 
patient must then lie supine for approximately 1 
hour to allow the cement to harden.14  
 
Benefits of vertebroplasty 
Current research into patients eligible for 
vertebroplasty focuses on two main areas: duration 
of back pain and age of fracture. However, these 
tend to be used interchangeably as back pain only 
occurs in symptomatic patients so it is assumed to 
correspond to the age of fracture. All randomised 
controlled studies used MRI15-19 to identify the 
presence of a fracture line or oedema in the 
vertebral body to indicate a vertebral fracture. 
However, studies varied in their stipulated limit for 
duration of back pain, from 2 weeks16 up to 1 
year.17,18, Localised pain at or adjacent to the level of 
the vertebral fracture shows significant association 
with improvement in pain levels following 
vertebroplasty as the localised pain helped the 
procedure to be targeted accurately.20  
 
One of the key beneficial outcomes of 
vertebroplasty is that it provides a statistically 
significant decrease in pain immediately after 
surgery. A Canadian meta-analysis quantified this as 
a 50–80% reduction, which remained for up to 2 
weeks.21 This was apparent when compared with 
both optimal medical management and a false 
procedure (where just local anaesthetic was 
injected). NICE, in 2013, carried out their own 
systematic review of the major evidence in patients 
with recent vertebral fractures (“recent” judged by 
NICE to be less than 6 weeks) and came to a similar 
conclusion.8 One of the largest randomised 
controlled trials, VERTOS II, showed statistically 
significant pain relief at 1 month, which was 
sustained for 1 year when compared with 
conservative management. Nonetheless this trial 
only included acute fractures (aged under 6 weeks 
as opposed to under 1 year as in some trials) and 
concluded that, in a select subgroup of these 
patients with persistent pain, vertebroplasty was a 
safe and cost-effective treatment.19 The mechanism 
for this improvement is not currently known, 
however one theory is that the cement 
interdigitating with the cancellous bone provides 
mechanical stability (as proven in joint 
replacements), which allows for biological healing of 
the fractured bone.22 Another proposed mechanism 
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for pain relief is through thermal cautery of the nerve 
endings, though this is perhaps less probable.21  
 
Furthermore, though mortality was not an outcome 
measured in the majority of the relevant research, it 
seems that vertebroplasty not only maintains but 
may even prolong life in comparison with medical 
management.8 One of the larger randomised 
controlled trials had significant improvements in 
quality of life assessed using the Oswestry Disability 
Index (ODI) at 1 week post-procedure, a reduction 
of 14 points (95% CI: −15.0 to −12.82, p-value 
<0.028) which was maintained over 36 months, 
where 4 points is the minimum for a clinical 
difference in back pain.15 Several studies used other 
indices and questionnaires to assess functionality 
and quality of life, with some good results, however 
not all reported the exact statistical data.8,17-19 
 
Despite the cost of the procedure and the fact that 
it does not eliminate the use of analgesia afterwards, 
NICE consider vertebroplasty to be cost effective in 
“people who have severe ongoing pain after a 
recent unhealed fracture despite optimal pain 
management and in whom the pain has been 
confirmed to be at the level of the fracture by 
physical examination and imaging”.8 Therefore, it is 
also financially advantageous to offer vertebroplasty 
as an option for the treatment of painful 
osteoporotic vertebral fractures when indicated.  
 
Disadvantages of vertebroplasty 
Literature surrounding the use of vertebroplasty in 
managing osteoporotic vertebral fractures has 
become more prevalent since the first randomised 
controlled trials in 2007,17,18,23 however the trial sizes 
tend to be small (typically fewer than 100 patients) 
with disparity in quality.  
 
One of the key disadvantages of vertebroplasty is 
that it is difficult to establish the long-term effects of 
the procedure due to the progression of the 
underlying osteoporosis, as well as associated 
comorbidities. This is exemplified by the conflicting 
evidence from current literature regarding pain 
reduction in particular, as described earlier.15-19 The 
VERTOS III study sought to investigate the natural 
course of pain in those with vertebral fractures and 
conservative management, concluding that it was 
bidirectional as half of the patients achieved pain 
reduction for up to 1 year.24 This demonstrates that 
it is challenging to identify which results are solely 
due to the vertebroplasty intervention as opposed 
to the confounding factors; which became evidently 
more problematic in the long term. There has been 
no difference in long-term pain relief when 
compared with both medical management and a 
false procedure,17,18 and patients presenting with 
pain surpassing 3 months are less likely to benefit 
from vertebroplasty.19  
 
To expect patients to present to clinicians, confirm 
any vertebral fractures, and undertake a 
vertebroplasty assessment before completing the 
procedure, all in a narrow timeframe may be difficult 
in practice, bringing viability into question. 
However, this may be due to a lack of awareness, 
perhaps compounded by the inconsistent evidence-
base — even the NICE guidelines on the 
recommendations are somewhat vague.8 If trusts 
were to formulate clear guidelines with specific 
criteria for the selection of patients based on the 
strongest evidence (such as pain of up to 6 weeks 
duration) and publicise it among relevant parties, it 
could allow those at risk to be identified more 
confidently and rapidly by clinicians. Depending on 
the restrictions and procedure uptake rate, this may 
have an important effect on the cost effectiveness of 
vertebroplasty for individual trusts.  
 
Furthermore, paired with any surgical procedure is 
the risk of complications and adverse effects, to 
which vertebroplasty is no exception. One review 
reported this rate as 1–10%.14 The commonest 
complication is cement extravasation, yet this may 
be asymptomatic and is dependent in part, on the 
volume of PMMA injected. Problems associated 
with extravasation are neural damage, cement 
emboli formation, thermal injury to surrounding 
structures, and the possibility of adjacent fracture or 
re-fracture.14,20 Figure 2 shows the extravasation of 
bone cement into the intervertebral disc5 (depicted 
by the arrow) in comparison to Figure 3 which shows 
a successful vertebroplasty of the L3 vertebra.25 One 
randomised controlled trial reported 1 patient out 
of 82 had experienced symptoms associated with 
cement extravasation. This patient was treated with 
immediate decompression via a bilateral 
laminectomy and made a full recovery in 2 months.15 
Therefore, prompt identification of complications of 
the procedure with clear management instructions 
may effectively reduce the impact of such negative 
effects. Though the procedure is minimally invasive, 
a risk of infection and bleeding is still present and 
adverse reactions to the PMMA have also been 
recorded.20 
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Figure 2 
 
Figure 3 
 
As some complications result from problems 
relating to the bone cement material, PMMA, there 
has been some keen interest in the development of 
new cement materials that are more physiologically 
compatible with bone. Examples of these biological 
cements are hydroxyapatite and calcium phosphate. 
They have the ability to integrate with patient’s 
bone so that, in time, bone can replace the synthetic 
cement. One aspect of the procedure involves lying 
still in a supine position to allow PMMA to harden, 
which may be difficult in typically elderly patients 
and could therefore restrict certain patients from 
undergoing the procedure. Developments in new 
bone cements may negate these impracticalities. As 
these biological cements are more flexible, they 
should be more compliant in their biomechanical 
properties and reduce stiffness in the vertebrae, 
which has been hypothesised to cause adjacent 
vertebral fractures when overloaded with force.5 The 
research into the relationship between 
vertebroplasty and the risk of subsequent vertebral 
fractures has shown that patients undergoing the 
procedure are at increased risk of adjacent level 
vertebral fractures.26,27 This is most likely to occur 
within 3 months of vertebroplasty,28 therefore 
minimisation of risk factors, such as having 
osteoporosis and intervertebral disc cement 
leakage is paramount.29  
Though NICE has established vertebroplasty as a 
cost-effective intervention in its most recent 
guidance, the initial costs estimated on average at 
£1,472 for 1–3 vertebrae is invariably higher than 
that of the staggered cost of frequent analgesic 
medication as would be the case for conservative 
management. Moreover, this estimate was provided 
on the basis of using traditional PMMA cement.8 
However length of inpatient stay is a factor that 
should also be taken into consideration. One trial 
found that the mean duration of hospitalisation 
during a 12-month period of follow-up was 33.45 
days in patients managed conservatively in 
comparison with 2.46 days in those treated with 
vertebroplasty.30 This would invariably have a large 
impact on cost effectiveness, most likely in favour of 
the vertebroplasty procedure. Notwithstanding, if 
the spectrum of patients using vertebroplasty in the 
context of osteoporotic vertebral fractures was 
widened, this may still have a substantial effect on 
the cost effectiveness of the procedure, which 
would need to be re-evaluated as long-term results 
may be complicated by risk of adjacent fracture. 
 
Conclusion 
The use of percutaneous vertebroplasty for the 
treatment of osteoporotic vertebral fractures is still 
a relatively new enterprise and, inevitably, more 
research is needed to inform the decisions of 
healthcare institutions as to its appropriate use. This 
research should aim to introduce greater variability 
in patient cohorts undergoing the procedure to 
expand understanding about which patients will 
benefit most from vertebroplasty. Nonetheless, 
there is sufficient data to draw the conclusion that 
vertebroplasty is worthwhile in reducing acute pain 
in the case of recent fractures. Conversely, its 
effectiveness in the long term and effect on risk of 
future fractures has not been reliably quantified; 
therefore, continual follow-up studies should seek to 
monitor this. Vertebroplasty does increase the 
likelihood of adjacent fracture, therefore traditional 
medication for osteoporosis is still indicated in these 
patients to maintain and build bone integrity.  
 
As an intervention, the minimally invasive surgical 
approach is favourable and shows equivalent or 
reduced mortality. Nonetheless, perhaps the 
greatest disadvantage of this intervention is 
arguably not the procedure itself, but the challenge 
of identifying when it may be indicated. Thus, 
improvements in the imaging and ageing of 
vertebral fractures may aid in expanding the eligible 
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patient pool, particularly in the treatment for acute 
fractures.   
	
What is known already: What this study adds/ highlights: 
• Not all vertebral fractures present clinically, with 
osteoporosis being the major cause of vertebral 
fractures 
• Osteoporosis is an age-related condition of 
reduced bone density and altered bone structure, 
with increasing prevalence in older populations 
• Vertebroplasty is an interventional treatment 
which can be used for pain relief in osteoporotic 
vertebral fractures  
• This review highlights the potential benefits and 
disadvantages surrounding the relatively modern 
treatment of percutaneous vertebroplasty. 
• Vertebroplasty is successful in reducing the acute 
pain in recent vertebral fractures 
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